15 completed. 15 Phase 3, 2 Phase 2.
By phase and status
Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma
Trials (filtered) newest first · largest first
All 15 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo - Diffuse Large B-cell Lymphoma Phase 3 Completed 423 2020-05-21 2026-04-08
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Rituximab, Gemcitabine - Diffuse Large B-Cell Lymphoma Phase 3 Completed 270 2020-02-07 2025-12-22
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL SIBP-02, Rituximab - Diffuse Large B-Cell Lymphoma Phase 3 Completed 421 2019-07-25 2023-12-27
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ Enzastaurin Hydrochloride, R-CHOP + placebo - Diffuse Large B-Cell Lymphoma Phase 3 Completed 256 2018-03-20 2025-01-23
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma Phase 3 Completed 1000 2017-11-16 2026-05-08
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Rituximab (RTX), Tafasitamab, Bendamustine (BEN) - Diffuse Large B-cell Lymphoma Phase 2 / Phase 3 Completed 453 2016-11-28 2025-07-17
MabionCD20 Compared to MabThera in Lymphoma Patients Rituximab, Doxorubicin, Vincristine - Diffuse Large B-Cell Lymphoma Phase 3 Completed 143 2015-12-01 2023-10-25
Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma RTXM83, Mabthera - Diffuse Large B-cell Lymphoma Phase 3 Completed 272 2013-05-01 2019-09-26
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Pixantrone + Rituximab, Gemcitabine + Rituximab - Diffuse Large B-cell Lymphoma, de Novo DLBCL Phase 3 Completed 312 2011-04-20 2021-11-19
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Phase 3 Completed 174 2010-11-01 2026-04-30
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Lenalidomide, Gemcitabine, Oxaliplatin - Diffuse Large B-cell Lymphoma Phase 2 / Phase 3 Completed 111 2010-09-02 2019-11-25
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Everolimus, Everolimus Placebo - Diffuse Large B-cell Lymphoma Phase 3 Completed 742 2009-07-24 2017-07-12
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP Lenalidomide, Placebo - Lymphoma, Diffuse Large B-cell Lymphoma Phase 3 Completed 650 2009-04-01 2021-07-26
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. Rituximab-HDS, Rituximab-CHOP - Diffuse Large B-Cell Lymphoma Phase 3 Completed 246 2005-05-01 2017-08-10
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Total-Body Irradiation, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission Phase 3 Completed 87 2003-10-01 2017-05-15
Narrower conditions Lymphoma, Large B-Cell, Diffuse (15) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Hematologic Neoplasms (3) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Multiple Myeloma (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Prolymphocytic (1) · Leukemia, Prolymphocytic, T-Cell (1)
Broader conditions Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphatic Diseases (15) · Lymphoproliferative Disorders (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Lymphoma, B-Cell (14) · Lymphoma (11) · Lymphoma, Non-Hodgkin (11) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Hematologic Diseases (3) · Neoplasms by Site (3)
Interventions Rituximab (9) · Cyclophosphamide (3) · Doxorubicin (3) · Gemcitabine (3) · Prednisone (3) · Vincristine (3) · Cyclosporine (2) · Cyclosporins (2) · Lenalidomide (2) · Mycophenolic Acid (2) · Oxaliplatin (2) · Peripheral Blood Stem Cell Transplantation (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · polatuzumab vedotin (2)
Sponsors Fred Hutchinson Cancer Center (2) · Hoffmann-La Roche (2) · CTI BioPharma (1) · Celgene (1) · Chipscreen Biosciences, Ltd. (1) · Denovo Biopharma LLC (1) · Gruppo Italiano Terapie Innovative nei Linfomi (1) · Incyte Corporation (1) · Mabion SA (1) · Novartis Pharmaceuticals (1) · Shanghai Institute Of Biological Products (1) · The Lymphoma Academic Research Organisation (1) · mAbxience Research S.L. (1)
Countries United States (9) · Italy (8) · France (7) · Germany (7) · Spain (7) · Austria (6) · China (6) · Poland (6) · Australia (5) · Czechia (5) · United Kingdom (5) · Brazil (4) · Canada (4) · Russia (4) · South Korea (4)
Top investigators Brenda Sandmaier (2) · Adrian Kilcoyne, MD (1) · Jun Zhu, Professor (1) · Sergio Cortelazzo, MD (1) · Simran B Singh, MS, GWCP (1) · Weili Zhao, Professor (1)
Results publications PMID 32499241 , PMID 21495023 , PMID 27093976 , PMID 28381416 , PMID 29253068 , PMID 31248843 , PMID 31879945 , PMID 31978225 , PMID 32250167 , PMID 32817282 , PMID 33278600 , PMID 34904799 , PMID 35710733 , PMID 35726803 , PMID 36626583 , PMID 36740991 , PMID 37864313 , PMID 40085955 , PMID 40991874 , PMID 40997297 , PMID 41056515 , PMID 42018318 , PMID 42407012 , PMID 42699559
NIH funding P30CA015704 (2) , 2008 (1) , 2014 (1) , 2017 (1) , 2018 (1) , P01CA018029 (1) , P01CA078902 (1)